NASDAQ: WHWKWhitehawk Therapeutics Inc Stock
$4.46-0.22 (-4.7%)
Updated Aug 14, 2026
WHWK Price
$4.46
Fair Value Price
-$4.41
Market Cap
$254.26M
52 Week Low
$1.57
52 Week High
$5.50
P/E
-3.88x
P/B
1.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$79.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$69M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WHWK Overview
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WHWK's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
WHWK
Ranked#115 of 461
Ranked#115 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.83 | A | |
| $114.47 | A | |
| $347.48 | A |
Be the first to know about important WHWK news, forecast changes, insider trades & much more!
WHWK News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WHWK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WHWK ($4.46) is overvalued by 201.13% relative to our estimate of its Fair Value price of -$4.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
WHWK ($4.46) is not significantly undervalued (201.13%) relative to our estimate of its Fair Value price of -$4.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
WHWK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more WHWK due diligence checks available for Premium users.
Valuation
WHWK fair value
Fair Value of WHWK stock based on Discounted Cash Flow (DCF)
Price
$4.46
Fair Value
-$4.41
Undervalued by
201.13%
WHWK ($4.46) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
WHWK ($4.46) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
WHWK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
WHWK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.88x
Industry
15.5x
Market
16.24x
WHWK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.39x
Industry
5.63x
WHWK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WHWK's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.6M
Profit Margin
0%
WHWK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$194.0M
Liabilities
$11.1M
Debt to equity
0.06
WHWK's short-term assets ($192.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WHWK's short-term assets ($192.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WHWK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WHWK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.5M
Investing
-$16.9M
Financing
$81.8M
WHWK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WHWK vs Biotech Stocks
Whitehawk Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.